Citius Pharmaceuticals, Inc. Share Price
Equities
CTXR
US17322U2078
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7263 USD | -2.68% | +1.37% | -3.99% |
Sales 2024 * | - | Sales 2025 * | 83.59M 6.69B | Capitalization | 135M 10.78B |
---|---|---|---|---|---|
Net income 2024 * | -36M -2.88B | Net income 2025 * | 5M 400M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.61 x |
P/E ratio 2024 * |
-3.39
x | P/E ratio 2025 * |
49.8
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.18% |
1 day | +7.85% | ||
1 week | -2.74% | ||
1 month | -16.83% | ||
3 months | +20.18% | ||
6 months | -0.84% | ||
Current year | -1.35% |
Managers | Title | Age | Since |
---|---|---|---|
Leonard Mazur
CEO | Chief Executive Officer | 79 | 30/06/13 |
Jaime Bartushak
DFI | Director of Finance/CFO | 57 | 26/11/17 |
Preeti Singh
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Myron Holubiak
BRD | Director/Board Member | 77 | 30/09/15 |
Dennis McGrath
BRD | Director/Board Member | 67 | 06/02/23 |
Leonard Mazur
CEO | Chief Executive Officer | 79 | 30/06/13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +1.51% | - |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 0.7263 | -2.68% | 537 567 |
30/04/24 | 0.7463 | +7.85% | 983,919 |
29/04/24 | 0.692 | +4.09% | 842,594 |
26/04/24 | 0.6648 | -9.25% | 2,776,465 |
25/04/24 | 0.7326 | +2.25% | 586,758 |
Delayed Quote Nasdaq, April 30, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.35% | 135M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- CTXR Stock